<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181024</url>
  </required_header>
  <id_info>
    <org_study_id>PP25195</org_study_id>
    <secondary_id>2009-018183-96</secondary_id>
    <nct_id>NCT01181024</nct_id>
  </id_info>
  <brief_title>A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1</brief_title>
  <official_title>A Single Ascending Dose Tolerability and Pharmacokinetic Study of RO5303253 With a Pilot Food-effect Investigation in Healthy Subjects and Exploratory Pharmacokinetic, Pharmacodynamic, and Safety Assessments in Chronic Hepatitis C Genotype 1 Patients Following 5 Days of Oral Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo controlled, 3 part study will assess the safety,
      tolerability and pharmacokinetics of RO5303253 in healthy volunteers and patients with
      chronic hepatitis C genotype 1. In Part A, cohorts of healthy volunteers will be randomized
      to receive single ascending doses of RO5303253 or placebo. In Part 2, healthy volunteers will
      receive a single dose of RO5303253 or placebo in a cross-over design (with a washout period
      of at least 7 days) to assess food effects on pharmacokinetics. In Part 3, patients with
      chronic hepatitis C will be randomized ro receive either RO5303253 or placebo for 5 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: Adverse events, laboratory parameters, ECG, blood pressure</measure>
    <time_frame>approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Plasma and urine concentrations of RO5303253 and its main metabolite RO1080713</measure>
    <time_frame>approximately 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of food intake on pharmacokinetics in healthy volunteers</measure>
    <time_frame>Days 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (viral responses) and drug resistance profiling in chronic hepatitis C patients</measure>
    <time_frame>From baseline to Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Hepatitis C, Chronic, Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A: HV ascending dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: HV food effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Hepatitis C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)</description>
    <arm_group_label>A: HV ascending dose</arm_group_label>
    <arm_group_label>B: HV food effect</arm_group_label>
    <arm_group_label>C: Hepatitis C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5303253</intervention_name>
    <description>Cohorts receiving single ascending doses</description>
    <arm_group_label>A: HV ascending dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5303253</intervention_name>
    <description>Single dose</description>
    <arm_group_label>B: HV food effect</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5303253</intervention_name>
    <description>Multiple doses</description>
    <arm_group_label>C: Hepatitis C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers or patients with chronic hepatitis C genotype 1, 18 to 60 years of
             age

          -  Patients must be treatment-na√Øve for antiviral therapy for chronic hepatitis C with
             interferon based therapy

          -  Body mass index (BMI) 18 - 32 kg/m2 inclusive, minimum weight 45 kg

          -  Females must be surgically sterile or menopausal

          -  Male subjects and their partners of childbearing potential must use 2 methods of
             contraception throughout the study and for 70 days after the last dose

        Exclusion Criteria:

          -  Pregnant or lactating women and male partners of women who are pregnant or lactating

          -  Women with reproductive potential

          -  Positive for hepatitis B or HIV (or hepatitis C for healthy volunteers) at screening

          -  For hepatitis C patients: decompensated liver disease or impaired liver function,
             evidence of cirrhosis documented at any time, presence or history of non-hepatitis C
             chronic liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Romania</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

